Table 4.
Relevant literature and the present study. Comparison with previous studies on definitive radiation therapy for adenocarcinoma/adenosquamous carcinoma of the uterine cervix
| Authors (year) |
Study design | No. | Stage I-II/III-IV | IGBT | Median follow-up (months) |
LC | OS | PFS | AE grade ≥ 3 |
|---|---|---|---|---|---|---|---|---|---|
| Niibe Y (2010) |
Multi, Retro | 61 | 0%/100% (stage III) |
Non-IGBT | N.R. | 3 y: 60%, 5 y: 36% |
3 y: 24%, 5 y: 20% |
3 y: 17%, 5 y: 13% |
13.1% (grade ≥ 2) |
| Rose PG (2014) |
Pooled, Retro | 182 | 75%/25% | Non-IGBT | N.R. | N.R. | 3 y: 49%, 5 y: 45% |
N.R. | N.R. |
| Chen JL (2014) |
Single, Retro | 35 | 74%/26% | Non-IGBT | 59 | 3 y: 64%, 5 y: 64% |
3 y: 66%, 5 y: 45% |
3 y: 39%, 5 y: 30% |
22.8% |
| Yin KC (2018) |
Single, PSM, Retro | 30 | 67%/33% | Non-IGBT | 40 | 3 y: 70%, 5 y: 70% |
3 y: 63%, 5 y: 46% |
3 y: 43%, 5 y: 43% |
3.3% |
| Miyasaka Y (2020) |
Multi, Retro | 71 | 51%/49% | Mixed | 37 | 3 y: 64%, 5 y: 62% |
3 y: 63%, 5 y: 50% |
3 y: 40%, 5 y: 36% |
N.R. |
| Zhang J (2020) |
Pooled, PSM, Retro | 331 | 66%/34% | Mixed | 55 | N.R. | 3 y: 52%, 5 y: 43% |
N.R. | N.R. |
| Present study | Multi, Retro | 36 | 25%/75% | IGBT | 39 | 3 y: 69% | 3 y: 68% | 3 y: 44% | 5.6% |
IGBT – image-guided brachytherapy; LC – local control; OS – overall survival; PFS – progression-free survival; AE – adverse event; Multi – multi-institutional study; Retro – retrospective study; N.R. – not reported; Pooled – pooled analysis; Single – single-institutional study; PSM – propensity score matching